Smith & Nephew stock
Price history
−6.99% over the period1 year: from 1,231.00 GBp (November 20, 2025) to 1,145.00 GBp (November 20, 2026), −6.99%.
Show chart data
Closing prices adjusted for splits: the last close of each month.
| Date | Close |
|---|---|
| November 20, 2026 | 1,145.00 GBp |
| October 30, 2026 | 1,107.50 GBp |
| September 30, 2026 | 1,009.00 GBp |
| August 28, 2026 | 1,062.50 GBp |
| July 31, 2026 | 1,158.50 GBp |
| June 30, 2026 | 1,090.50 GBp |
| May 29, 2026 | 1,111.00 GBp |
| April 30, 2026 | 1,137.00 GBp |
| March 31, 2026 | 1,185.00 GBp |
| February 27, 2026 | 1,371.50 GBp |
| January 30, 2026 | 1,242.00 GBp |
| December 31, 2025 | 1,238.50 GBp |
| November 28, 2025 | 1,254.50 GBp |
| November 20, 2025 | 1,231.00 GBp |
At a glance
The company
Develops, manufactures and markets medical devices for orthopaedic surgery, sports medicine, ENT and advanced wound management
Latest results
Quarter to June 30, 2026 · EPS $0.47 (estimate $0.47)
Next event
TickerLandia's take on Smith & Nephew
- Cheaper than similar companies: trailing 12-month P/E 21 vs 28 (−27%) in a group of 10.
- Strong point: Dividend (74/100 in its group). Weak point: Financial strength (30/100).
Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks
Where the price stands
−18.01% from the 52-week high
Analysts · 18 analysts
Average target1,256.53 GBp+9.74% vs. price
Buy 4 · Hold 13 · Sell 1 · Hold
TickerLandia Fingerprint: Smith & Nephew
Compared with similar companies: very low price.
Financials and price compared with 31 companies in the medical devices industry, worldwide. Momentum and risk compared with 1,160 European stocks.
Pricevery low14
How much it costs relative to what it produces.
Metric Value Position in group P/E (trailing 12 months) 20.8 16 EV/EBITDA 9.25 5 Forward P/E 13.2 8 Price/book 2.52 27 Price/sales 1.52 11 Profitabilityaverage49
How much it earns on revenue and capital.
Metric Value Position in group Operating margin 14.2% 34 ROE 11.9% 53 ROA 5.2% 37 Gross margin 68.4% 73 Net margin 10.1% 50 Earnings stabilityhigh73
How steady its margins were over the last five annual reports.
Metric Value Position in group Margin variabilitycounts in reverse: lower means more earnings stability 1.0% 89 Loss-making yearscounts in reverse: lower means more earnings stability 0 of 5 annual reports 56 Growthaverage42
How fast revenue and earnings are growing.
Metric Value Position in group Earnings growth (year over year) +5.70% 47 Revenue growth (year over year) +4.60% 34 Average revenue growth (3 years) +5.73% 47 Financial strengthlow30
How well it would weather a hard period: debt, liquidity, interest.
Metric Value Position in group Net debt/EBITDAcounts in reverse: lower means more financial strength 2.07 22 Debt/equitycounts in reverse: lower means more financial strength 0.73 21 Current ratio 2.14 63 Interest coverage 6.26 15 Dividendhigh74
How much it returns to shareholders, and for how long.
Metric Value Position in group Consecutive dividend years 34 years 86 Dividend yield 2.5% 79 Payout ratio 53.5% 57 Market momentumaverage53
How the stock has moved compared with the market.
Metric Value Position in group Relative strength (3 months) +10.80% 78 Relative strength (6 months) +0.83% 57 Distance from 200-day average −0.13% 53 1-year return −6.99% 26 Riskaverage45
How much the price swings.
Metric Value Position in group Beta (1 year) 0.49 27 Volatility (60 days) 26.1% 44 Maximum drawdown (12 months) 28.4% 64
Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 22, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated
Valuation
Smith & Nephew is cheaper than similar companies
Smith & Nephew's P/E (trailing 12 months): 20.8, −27% against the median of a group of 10 similar companies (28.3).
Compared with 10 similar companies
| Metric | Smith & Nephew | Position in the group | Band |
|---|---|---|---|
| P/E (trailing 12 months) | 20.8 | Low | |
| Forward P/E | 13.2 | Low | |
| Operating margin | 14.2% | Middle | |
| ROE | 11.9% | Middle | |
| Debt/equity | 0.73 | Middle |
Grey band: the middle half of the group; tick: the median; dot: Smith & Nephew. All multiples and dividends
TickerLandia analysisHow it is calculated
The financials
The business in numbers
Revenue
$3.1B
Latest quarter · Q2 2026
Net income
$303M
Latest quarter · Q2 2026
Quarterly net margin
9.8%
Latest quarter · Q2 2026
Numbers and valuation
Full valuation- Market cap
- £9.57B
- P/E
- 20.8
- EPS
- 55.00 GBp
- Volume
- 3.01M
- Daily trading
- €57.53M
- Dividend yield
- 2.57%
- Last ex-dividend on October 1, 2026
How Smith & Nephew is changing
All resultsRevenue grew 6.2% a year on average over the last 5 years
Operating margin rose from 12.6% to 14.2%
Profits turn into cash: free cash flow equal to 126% of net income
Returns
Smith & Nephew returns with dividends
£1,000 invested in Smith & Nephew 5 years ago, on November 22, 2021, would be worth £1,030 today with dividends reinvested: +3.05% in total, +0.60% per year. On price alone it would be £900 (−10.02%).
| Period | Smith & Nephew | FTSE 100 | £1,000 becomes |
|---|---|---|---|
| 1 month | +5.29% | −3.60% | £1,053 |
| 6 months | 0.00% | −0.82% | £1,000 |
| Year to date | −7.55% | +4.18% | £925 |
| 1 year | −4.48% | +8.59% | £955 |
| 3 years | +21.58% | +38.02% | £1,216 |
| 5 years | +3.05% | +42.60% | £1,030 |
| 10 years | +31.84% | +52.65% | £1,318 |
Over the last 6 months it has done better than 22% of the stocks in the Healthcare sector.
From 1 year up with dividends reinvested, before taxes; under a year price only. FTSE 100: price only. Calculate your investment
The chart in detail
Smith & Nephew: technical analysis
Smith & Nephew shows no clear trend: the price and its 50- and 200-session averages are not aligned. The price is 42.5% below its highest close since January 1, 1990 (1,990.00 GBp, September 2, 2019).
- Trend
- No clear trend
- RSI (14 sessions)
- 55
- Between 30 and 70
- vs 200-session average
- −0.13%
Support and resistance
Price areas where Smith & Nephew has stopped several times in the last year. They describe the chart; they are not forecasts.
- Resistance1,208.20 GBp+5.52%5 touches, last on November 5, 2026
- Resistance1,179.04 GBp+2.97%4 touches, last on July 17, 2026
- Resistance1,163.13 GBp+1.58%4 touches, last on October 23, 2026
- Last price1,145.00 GBp
- Support1,104.75 GBp−3.52%2 touches, last on July 23, 2026
- Support1,080.50 GBp−5.63%4 touches, last on November 4, 2026
- Support1,048.00 GBp−8.47%2 touches, last on August 21, 2026
Volatility and risk
Over the last year it has moved less than the FTSE 100.
- Beta (1 year) vs FTSE 100
- 0.49
- Volatility (60 sessions, annualised)
- 26.1%
- Largest fall in the last year
- −28.37%
Close of November 20, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it
Smith & Nephew: seasonality
Average monthly price change over 37 years
Over the last 37 years, the strongest month for Smith & Nephew has been December: +3.24% on average, positive in 22 years out of 36. The weakest has been March: −1.86% on average, positive in 13 years out of 37. November, the current month, has been positive in 19 years out of 36 (+1.32% on average).
Show chart data
| Month | Average | Median | Positive years |
|---|---|---|---|
| January | +0.33% | −0.16% | 15 of 36 |
| February | +2.43% | +2.31% | 22 of 37 |
| March | −1.86% | −2.13% | 13 of 37 |
| April | +1.78% | +0.70% | 19 of 37 |
| May | +0.01% | −0.08% | 16 of 37 |
| June | +0.78% | 0.00% | 18 of 37 |
| July | +0.53% | −0.38% | 15 of 37 |
| August | +0.62% | −0.93% | 15 of 37 |
| September | −0.61% | −0.31% | 14 of 37 |
| October | −0.52% | −1.04% | 15 of 37 |
| November | +1.32% | +0.49% | 19 of 36 |
| December | +3.24% | +3.71% | 22 of 36 |
Price change only, dividends excluded. Past seasonality does not predict future moves.
The company
Smith & Nephew and its competitors
Smith & Nephew's largest business is its Orthopaedics segment, which covers knee and hip implants, trauma and extremities products for the stabilization of severe fractures, and other reconstruction products. Its other two segments are Sports Medicine & ENT, offering minimally invasive joint repair instruments, arthroscopic enabling technologies and ear, nose and throat solutions, and Advanced Wound Management, which includes wound care products, bioactives and regenerative medicine products, and negative pressure wound therapy and hydrosurgery systems.
- Headquarters
- Watford, United Kingdom
- Employees
- 17,000
- Founded
- 1856
- Chief executive
- Deepak Nath
| Company | Market cap | Operating margin | P/E (trailing 12 months) | 6 months |
|---|---|---|---|---|
| Smith & NephewSN. | $12.57B | 14.2% | 20.8 | 0.00% |
| DemantDEMANT | $10.7B | 17.2% | 30.1 | +44.56% |
| Sonova HoldingSOON | $20.67B | 20.6% | 28.9 | +43.74% |
| GetingeGETI.B | $7.39B | 14.3% | 26.6 | +40.54% |
| SectraSECT.B | $6.24B | 20.6% | 105.8 | +21.58% |
| Koninklijke PhilipsPHIA | $28.35B | 8.8% | 26.7 | +15.14% |
Same industry or related industries, similar size. Compare Smith & Nephew with its competitors · Full profile
